Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CDK4 | P11802 | 16/20 | 1.00 |
| ▸ | CCND1 | P24385 | 16/20 | 1.00 |
| ▸ | CCND3 | P30281 | 3/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 3/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 2/20 | 1.00 |
| ▸ | CDK9 | P50750 | 2/20 | 1.00 |
| ▸ | TTK | P33981 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | CCNH | P51946 | 1/20 | 1.00 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 1.00 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 1.00 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lerociclib SCHEMBL22832157 | 1.00 | CDK2 (1.00) | CDK2CDK4CCND1CCND3CDK6 | |
| Lerociclib SCHEMBL30175009 | 1.00 | CDK2 (1.00) | CDK2CDK4CCND1CCND3CDK6 | |
| Lerociclib SCHEMBL29409995 | 0.99 | CDK2 (0.98) | CDK2CDK4CCND1CCND3CDK6 | |
| Lerociclib SCHEMBL23711495 | 0.99 | CDK2 (0.98) | CDK2CDK4CCND1CCND3CDK6 | |
| Lerociclib SCHEMBL29409994 | 0.99 | CDK2 (0.98) | CDK2CDK4CCND1CCND3CDK6 | |
| SCHEMBL15249273 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCND3CDK6 | |
| SCHEMBL24413774 | 0.92 | CDK2 (0.85) | CDK2CDK4CCND1CCND3CDK6 | |
| SCHEMBL20980212 | 0.92 | CDK2 (0.87) | CDK2CDK4CCND1CCND3CDK6 | |
| Trilaciclib SCHEMBL29356370 | 0.91 | CDK2 (1.00) | CDK2CDK4CCND1CCND3CDK6 | |
| Trilaciclib SCHEMBL29763763 | 0.91 | CDK2 (1.00) | CDK2CDK4CCND1CCND3CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144778-A1 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS | OLEMA PHARMACEUTICALS, INC. (US) | 2026-05-28 | — | — | US | claimed |
| WO-2026103886-A1 | PHARMACEUTICAL COMPOSITION, KIT AND USE THEREOF | 浙江扬厉医药技术有限公司 | 2026-05-21 | — | — | WO | claimed |
| WO-2026101937-A1 | COMPOSITIONS COMPRISING (Z)-ENDOXIFEN AND A CDK4/6 INHIBITOR AND METHODS OF USE THEREOF | ATOSSA THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260103461-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | OLEMA PHARMACEUTICALS INC (US) | 2026-04-16 | — | — | US | claimed |
| EP-4704841-A1 | IMLUNESTRANT OR SALTS THEREOF FOR USE IN TREATING AND PREVENTING CENTRAL NERVOUS SYSTEM (CNS) METASTASES IN SUBJECTS HAVING ER+ BREAST CANCER | Eli Lilly and Company (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | claimed |
| EP-4683635-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | Boundless Bio, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| EP-4653019-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE FOR TREATING BREAST CANCER | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-11-26 | — | — | EP | claimed |
| US-20250352531-A1 | Dosage Regimen for the Treatment of Cancer | ASTRAZENECA AB (SE) | 2025-11-20 | — | — | US | claimed |
| EP-3973964-A1 | QUINOLINE DERIVATIVE USED FOR COMBINATION TREATMENT OF SMALL CELL LUNG CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3973963-A1 | QUINOLINE DERIVATIVES FOR TREATMENT OF HEAD AND NECK CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3967310-A1 | QUINOLINE DERIVATIVE USED FOR SOFT TISSUE SARCOMA COMBINATION THERAPY | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-03-16 | — | — | EP | claimed |
| US-11261193-B2 | Morphic forms of G1T38 and methods of manufacture thereof | GI Therapeutics, Inc. (US) | 2022-03-01 | — | — | US | claimed |
| US-20220054488-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2022-02-24 | — | — | US | claimed |
| EP-3957631-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-10 | — | — | US | claimed |
| WO-2022017524-A1 | PYRIDONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 深圳晶泰科技有限公司 | 2022-01-27 | — | — | WO | claimed |
| WO-2021226263-A1 | COMBINATIONS | RECURIUM IP HOLDINGS, LLC (US) | 2021-11-11 | — | — | WO | claimed |
| US-20200123168-A1 | MORPHIC FORMS OF G1T38 AND METHODS OF MANUFACTURE THEREOF | G1 THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123168-A1 | MORPHIC FORMS OF G1T38 AND METHODS OF MANUFACTURE THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB8A, UGT1A8 | CDK2 1521/4885CDK4 2034/4885CCND1 362/4885 |
| US-20260103461-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESRRA, GPER1, ESR2 | CDK2 1041/4885CDK4 2226/4885CCND1 2445/4885 |
| US-20220054488-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | CDK4, CDK6, CDK2 | CDK2 3/4885CDK4 1/4885CCND1 26/4885 |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | WEE1, ERBB3, ERBB2 | CDK2 30/4885CDK4 50/4885CCND1 356/4885 |
| US-20250352531-A1 | Dosage Regimen for the Treatment of Cancer | CDK4, CDK3, CDK8 | CDK2 8/4885CDK4 1/4885CCND1 22/4885 |
| US-11261193-B2 | Morphic forms of G1T38 and methods of manufacture thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB8A, COG8 | CDK2 3293/4885CDK4 3334/4885CCND1 687/4885 |
| US-20260144778-A1 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS | ESR1, ESR2, PGR | CDK2 25/4885CDK4 4/4885CCND1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.